Nurix receives $700M upfront from Roche to co-develop BTK degrader bexobrutideg; potential $2.3B total

Nurix Therapeutics, Inc.

Upfront cash payment of $700 million; potential development, regulatory and sales milestones up to $2.3 billion total.
Development costs shared 40% Nurix / 60% Roche; U.S. profits and losses split equally.
Ex-U.S. royalties range from low-teens to high-teens on net sales; Roche leads commercialization outside U.S.
Expansion into immunology and neurology: Phase 2 trials planned in multiple sclerosis and chronic spontaneous urticaria.
Co-development and co-commercialization in U.S. across malignant hematology; Nurix becomes fully integrated biotech.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Nurix Therapeutics, Inc. entered into Collaboration Agreement with F. Hoffmann-La Roche Ltd. and Genentech, Inc. valued at $700.0 million (effective 2026-06-06).

Action: entry
Agreement: license
Counterparty: F. Hoffmann-La Roche Ltd. and Genentech, Inc.
Value: $700.0 million
Effective: 2026-06-06

Exact text from the filing

On June 6, 2026, Nurix Therapeutics, Inc. (" Nurix ") entered into a License and Collaboration Agreement (the " Collaboration Agreement "), dated as of June 8, 2026, with F. Hoffmann-La Roche Ltd. and Genentech, Inc. (collectively, " Roche ")

View on SEC.gov

745 material agreements filed in the last 30 days. Browse all material agreements →

Nurix Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001549595-26-000030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.